Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-931699 in active systemic lupus erythematosus
2014-002184-14Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing BMS-931699 + limited standard of care with Placebo + limited standard of care (2 arms). Primary endpoint: BICLA response rate at Day 169. Started Dec 2014; status: completed.
02
Drugs
lulizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2014-002184-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002184-14.